- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT05804448
Effekt af højde på postdural punktering hovedpine efter kejsersnit
Effekt af højde på postdural punktur hovedpine efter kejsersnit: en prospektiv, multicenter kohorteundersøgelse
The aim of this study is to examine the effects of altitude (high altitude versus low altitude) on incidence and severity of postural puncture headache (PDPH) following spinal anaesthesia for caesarean delivery. The investigators hypothesized that the risk of PDPH would be higher in highlander parturients than in lowlander parturients.
Studieoversigt
Status
Betingelser
Detaljeret beskrivelse
This will be a prospective cohort study conducted in two different altitudes in Nepal. The high-altitude site is in Jumla, approximately 2514 m above the sea level, and a low altitude city is Dharan, located at 350 m from sea level.
The investigators will screen the eligible participant admitted to the in-patient obstetric unit. The investigator will also record patient baseline characteristics, preoperative anxiety, antenatal depression, presence of chronic pain conditions or preexisting headache. Spinal anaesthesia will be administered in the sitting position at the L3-L4 or L4-L5 interspace using a 25-G pencil point spinal needle (Pencan® 25-gauge).
The diagnosis of post-dural puncture headache will be based on the international headache society ICDH-3 criteria
Undersøgelsestype
Tilmelding (Anslået)
Kontakter og lokationer
Studiekontakt
- Navn: Asish Subedi, MD
- Telefonnummer: 9842040604
- E-mail: ashish.subedi@bpkihs.edu
Studiesteder
-
-
Karnali
-
Jumla, Karnali, Nepal, 2069
- Rekruttering
- Karnali Academy of Health Sciences
-
Kontakt:
- Robin Khapung, MD
- Telefonnummer: 9849481562
- E-mail: robinkhapung@hotmaail.com
-
-
Koshi
-
Dharān, Koshi, Nepal, 56700
- Rekruttering
- BP Koirala Institute of Health Sciences (BPKIHS)
-
Kontakt:
- Asish Subedi, MD
- Telefonnummer: 2013 977-25-525555
- E-mail: ashish.subedi@bpkihs.edu
-
Ledende efterforsker:
- Asish Subedi, MD
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Parturients planned for elective and non-elective (category 2 & 3) caesarean section under spinal anaesthesia.
Beskrivelse
Inclusion Criteria:
- Parturient, aged more than or equal to 18 years
- American society of Anesthesiologist 2 and 3
- Scheduled for elective and non-elective (category 2 & 3) caesarean delivery with spinal anesthesia
- Native to their resident altitude i.e., those born, raised, and have continuously lived at the same altitude, at least for the past 1 year.
Exclusion Criteria:
- Hypertensive disorder
- Cerebrovascular disease
- Mental disorder (schizophrenia and other psychotic disorders)
- Known fetal anomalies
- Contraindication to spinal anaesthesia.
- Those requiring general anaesthesia for delivery due to failed spinal anesthesia
- Major post-delivery complications (severe haemorrhage, sepsis, or ICU admission)
- Those who migrate from their resident altitude (either low to high or vice versa) within 7 days post-delivery will also be excluded.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Kohorter og interventioner
Gruppe / kohorte |
|---|
|
High-altitude group
Parturient who are native to their resident altitude, i.e. residing at the altitude above 2500 m from sea level will receive spinal anesthesia for caesarean section. |
|
Low-altitude group
Parturient who are native to their resident altitude, i.e. residing at the altitude below 500 m from sea level will receive spinal anesthesia for caesarean section. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of patients with postdural puncture headache
Tidsramme: up to 7 days after spinal anesthesia
|
The diagnosis of post-dural puncture headache will be based on the international headache society ICDH-3 criteria: a headache that occurs within 5 days of a dural puncture, is located in the occipital and/or frontal areas, worsens within 15 min of sitting or standing and alleviates within 15 min after lying down, associated with at least one of the following features: neck stiffness, nausea, vomiting, photophobia, and tinnitus, and resolves either spontaneously within 1 week or within 48 h after effective treatment. |
up to 7 days after spinal anesthesia
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of patients with severity of postdural puncture headache
Tidsramme: up to 7 days after spinal anesthesia
|
using a numeric rating scale (NRS), with 0= NO pain 10=worst imaginable pain, and classified as none (NRS=0), mild (1-3), moderate (4-6), and severe (7-10) |
up to 7 days after spinal anesthesia
|
|
Number of patients with non-postdural puncture headache
Tidsramme: up to 7 days after spinal anesthesia
|
Headache that is not related to posture |
up to 7 days after spinal anesthesia
|
|
Number of patients who received treatment for postdural puncture headache
Tidsramme: up to 1 month after occurrence of PDPH
|
paracetamol, NSAID's, caffeine, opioids, glossopharyngeal nerve block, sphenopalatine ganglion block and epidural blood patch |
up to 1 month after occurrence of PDPH
|
Samarbejdspartnere og efterforskere
Samarbejdspartnere
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 533/2022 P
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .